Posted by Michael Wonder on 05 Dec 2023
Vanda Pharmaceuticals announces that US FDA accepts new drug application for tradipitant for the treatment of gastroparesis
4 December 2023 - Vanda Pharmaceuticals today announced that the US FDA has accepted the filing of Vanda's new drug application for tradipitant for the treatment of symptoms of gastroparesis.
The FDA has set 18 September 2024 as the target date for its decision under the Prescription Drug User Fee Act.
